Increased frequency of CD14 HLA-DR-/low cells in type 2 diabetes patients with poor glycemic control Article uri icon

abstract

  • Aims: Type 2 diabetes (T2DM) is associated with alterations of the immune response and T2DM patients have an increased risk for infections and certain sorts of cancers. Although CD14 HLA-DR-/low cells have emerged as important mediators of immunosuppression in several pathologies, including cancer and non-malignant diseases, the presence of these cells in T2DM is not fully characterized. Methods: In this study, we evaluated the frequency of CD14 HLA-DR-/low cells in non-obese T2DM patients and their association with glycemic control. Peripheral blood mononuclear cells were isolated from healthy controls (HC, n = 24) and non-obese T2DM patients (n = 25), the population was evaluated by flow cytometry, and an analysis of correlation between cell frequencies and clinical variables was performed. Results: CD14 HLA-DR-/low monocytes were expanded in patients with T2DM compared to HC regardless of weight. Among the subjects with T2DM, the frequency of CD14 HLA-DR-/low was higher in patients with poor glycemic control (HbA1c > 9%25) compared to those with better glycemic control (HbA1c < 9%25) and, positively correlated with the years since the diagnosis of T2DM, the age of the patients and the glycemic index. Conclusions: An increased frequency of CD14 HLA-DR-/low cells in the blood of T2DM patients was recorded. The influence of hyperglycemia seems to be independent of obesity, but related to glycemic control and age. © 2022 American Society for Histocompatibility and Immunogenetics
  • Aims: Type 2 diabetes (T2DM) is associated with alterations of the immune response and T2DM patients have an increased risk for infections and certain sorts of cancers. Although CD14%2bHLA-DR-/low cells have emerged as important mediators of immunosuppression in several pathologies, including cancer and non-malignant diseases, the presence of these cells in T2DM is not fully characterized. Methods: In this study, we evaluated the frequency of CD14%2bHLA-DR-/low cells in non-obese T2DM patients and their association with glycemic control. Peripheral blood mononuclear cells were isolated from healthy controls (HC, n = 24) and non-obese T2DM patients (n = 25), the population was evaluated by flow cytometry, and an analysis of correlation between cell frequencies and clinical variables was performed. Results: CD14%2bHLA-DR-/low monocytes were expanded in patients with T2DM compared to HC regardless of weight. Among the subjects with T2DM, the frequency of CD14%2bHLA-DR-/low was higher in patients with poor glycemic control (HbA1c > 9%25) compared to those with better glycemic control (HbA1c < 9%25) and, positively correlated with the years since the diagnosis of T2DM, the age of the patients and the glycemic index. Conclusions: An increased frequency of CD14%2bHLA-DR-/low cells in the blood of T2DM patients was recorded. The influence of hyperglycemia seems to be independent of obesity, but related to glycemic control and age. © 2022 American Society for Histocompatibility and Immunogenetics

publication date

  • 2022-01-01